Brind.
  1. SciBase is seeking to expand its indication via a 510(k) submission while Nevisense already holds CE mark approval in Europe.

Highmark grants positive medical policy for Nevisense, boosting SciBase's U.S. outlook

1 report, 1 independent Updated 00:00
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

SciBase announced that Nevisense received its first positive medical policy from Highmark Blue Cross Blue Shield on October 14, 2026. This decision changes the reimbursement landscape for Nevisense, allowing eligible use of the technology to move from a cash-pay model into covered care through a major U.S. private insurer. This approval introduces a new growth driver for SciBase.

From prnewswire.com

Why it matters

Some supportBrind's analysis of the reports

The coverage expands the number of dermatology practices and patients who can access Nevisense under a reimbursed model. This removes one of the most significant barriers to scale for the technology in the United States, creating a substantially larger market opportunity.

SciBase is seeking to expand its indication via a 510(k) submission while Nevisense already holds CE mark approval in Europe.

From prnewswire.com

Who's involved

  • HighmarkGranted the first positive medical policy for Nevisense

Keep exploring

Part of

SciBase is seeking to expand its indication via a 510(k) submission while Nevisense already holds CE mark approval in Europe. All 1 developments

The entities involved

Coverage

Newest first; wire copies grouped